Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The 20 Most sultry Style of the Time - 2Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
- 3Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- 4Creative Do-It-Yourself Ventures for Each Expertise Level
- 5Figure out How to Amplify Innovation and Infotainment Frameworks for Senior Drivers in SUVs
- How the Iran war may affect your money and bills
- Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- Audits of Espresso Types: Which Mix Is for You?
- These Cities Led Global Jet-Setting In 2025, According To New Data
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- Watch This Glacier Race into the Sea
- Trump signs a law returning whole milk to school lunches
- Antivirus Programming for Exhaustive Security
- New UPS distribution center in Taiwan doubles capacity, productivity
